Arturo Molina MD plans Rule 144 sale of 9,514 PTGX shares on NASDAQ

Rhea-AI Filing Summary

Protagonist Therapeutics (PTGX) stockholder Arturo Molina MD has filed a Rule 144 notice to sell 9,514 common shares through Morgan Stanley Smith Barney on NASDAQ. The planned sale has an aggregate market value of $784,714.72, compared with a total of 62,515,666 common shares outstanding. The shares relate to restricted stock that vested under a registered plan on 01/20/2026, with services rendered as the form of payment.

The form also discloses that the same seller previously sold 2,712 common shares on 11/17/2025 for gross proceeds of $229,896.24. By signing, the seller represents they are not aware of any undisclosed material adverse information about Protagonist Therapeutics’ operations.

Insights

Equity capital markets analyst

Small Rule 144 sale by a PTGX stockholder, routine and limited in size.

This notice shows a Protagonist Therapeutics stockholder, Arturo Molina MD, planning to sell 9,514 common shares with an aggregate market value of $784,714.72. These shares come from restricted stock that vested on 01/20/2026 under a registered plan and were earned as compensation for services rendered, which is a standard equity compensation mechanism.

The filing also lists a prior sale of 2,712 common shares on 11/17/2025 for gross proceeds of $229,896.24. In the context of 62,515,666 common shares outstanding, the amounts involved are small. The certification that the seller is not aware of undisclosed material adverse information is a normal Rule 144 representation rather than a new signal about company fundamentals.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney Operations Department 2000 Westchester Ave Purchase NY 10577-2530	9514	784714.72	62515666	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/20/2026	Restricted stock vesting under a registered plan	Issuer			9514	01/20/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MOLINA ARTURO MD 7707 GATEWAY BLVD., SUITE 140 NEWARK CA 94560-1160	Common	11/17/2025	2712	229896.24

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the PTGX Rule 144 filing by Arturo Molina MD disclose?

The filing shows that Arturo Molina MD plans to sell 9,514 PTGX common shares under Rule 144 through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $784,714.72.

How large is the planned PTGX share sale under this Rule 144 notice?

The notice covers 9,514 common shares of Protagonist Therapeutics, compared with 62,515,666 common shares outstanding as stated in the filing.

When and how were the PTGX shares being sold acquired?

The 9,514 shares were acquired on 01/20/2026 as restricted stock vesting under a registered plan from the issuer, with services rendered listed as the form of payment.

What prior PTGX share sales by this holder are disclosed?

The document reports that the same seller disposed of 2,712 common shares on 11/17/2025, generating $229,896.24 in gross proceeds.

What representation does the seller make about PTGX information in this notice?

By signing, the seller represents that they do not know of any material adverse information about Protagonist Therapeutics’ current or prospective operations that has not been publicly disclosed.

Which broker and exchange are involved in the planned PTGX share sale?

The filing lists Morgan Stanley Smith Barney as broker, with the common shares to be sold on the NASDAQ exchange.